- **Name:** Lucy Ann Godley

- **Current Position:**
  Professor, Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, USA

- **Country:** USA

- **Educational Background:**

1980-1984	Amity Regional Senior High School, Woodbridge, CT Graduated valedictorian from a class of 400 students
1984-1988	B.A. Harvard and Radcliffe Colleges, Cambridge, MA summa cum laude in Biochemical Sciences Recipient of the Elizabeth Cary Agassiz and the Harvard College Scholarships Dean's list each semester Henderson prize for outstanding biochemistry thesis
1988-1994	Ph.D. University of California, San Francisco, San Francisco, CA Medical Scientist Training Program and Pre-IRTA Fellow, National Institutes of Health, NCI, Bethesda, MD Thesis: The effects of altered p53 expression on tumorigenesis and development Advisor: Harold E. Varmus, M.D.
1996-1997	M.D. Northwestern University School of Medicine, Chicago, IL

- **Professional Experiences:**

2003-2010	Assistant Professor, Section of Hematology/Oncology
2010-2014	Associate Professor, Section of Hematology/Oncology
2015-present	Professor, Section of Hematology/Oncology, Department of Medicine
2016-present	Professor, Department of Human Genetics (secondary appointment) Ph.D.-Granting Committee, Program, Institute, and Center Appointments

2003-present	The University of Chicago Comprehensive Cancer Center
2004-present	Committee on Cancer Biology

• Main Scientific Publications:

1. Guidugli, L., Johnson, A.K., Alkorta-Aranburu, G., Nelakuditi, V., Arndt, K., Churpek, J.E., **Godley, L.A.**, Townsley, D., Young, N.S., Fitzpatrick, C., Del Gaudio, D., Das, S., and Li, Z. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. *Leukemia* 31: 1226-1229 (2017).
2. Khan, N., Hantel, A., Knoebel, R.W., Artz, A., Larson, R.A., **Godley, L.A.**, Thirman, M.J., Liu, H., Churpek, J.E., King, D., Odenike, O., and Stock, W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. *Leuk Lymphoma* 58: 1-7 (2017).
3. Wang, A.Y., Weiner, H., Green, M., Chang, H., Fulton, N., Larson, R.A., Odenike, O., Artz, A.S., Bishop, M.R., **Godley, L.A.**, Thirman, M.J., Kosuri, S., Churpek, J.E., Curran, E., Pettit, K., Stock, W., and Liu, H. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. *J Hematol Oncol* 11: 4 (2018).
4. Drazer, M.W., Kadri, S., Sukhanova, M., Patil, S.A., West, A.H., Feurstein, S., Calderon, D.A., Jones, M.F., Weipert, C.M., Daugherty, C.K., Ceballos-López, A.A., Raca, G., Lingen, M.W., Li, Z., Segal, J.P., Churpek, J.E., and **Godley, L.A.** Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. *Blood Adv* 2: 146-150 (2018).
5. Wei, X., Calvo-Vidal, M.N., Chen, S., Wu, G., Revuelta, M.V., Sun, J., Zhang, J., Walsh, M.F., Nichols, K.E., Joseph, V., Snyder, C., Vachon, C.M., McKay, J.D., Wang, S.P., Jayabalan, D.S., Jacobs, L.M., Becirovic, D., Waller, R.G., Artomov, M., Viale, A., Patel, J., Phillip, J.M., Chen-Kiang, S., Curtin, K., Salama, M., Atanackovic, D., Niesvizky, R., Landgren, O., Slager, S.L., **Godley, L.A.**, Churpek, J., Garber, J.E., Anderson, K.C., Daly, M.J., Roeder, R.G., Dumontet, C., Lynch, H.T., Mullighan, C.G., Camp, N.J., Offit, K., Klein, R.J., Yu, H., Cerchietti, L., and Lipkin, S.M. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. *Cancer Res.* 78: 2747-2759 (2018)